Correction: The dual PI3K/mTOR inhibitor dactolisib elicits anti-tumor activity  in vitro  and  in vivo

Fei Shi; Jinying Zhang; Hongyu Liu; Liangliang Wu; Hongyu Jiang; Qiyan Wu; Tianyi Liu; Meiqing Lou; Hao Wu

doi:10.18632/oncotarget.25063

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: The dual PI3K/mTOR inhibitor dactolisib elicits anti-tumor activity in vitro and in vivo

PDF | How to cite

Oncotarget. 2018; 9:17255-17255. https://doi.org/10.18632/oncotarget.25063

Metrics: PDF 1566 views | ?

Fei Shi^1,*, Jinying Zhang^2,*, Hongyu Liu³, Liangliang Wu³, Hongyu Jiang⁴, Qiyan Wu³, Tianyi Liu³, Meiqing Lou^1,# and Hao Wu^5,#

¹Department of Neurosurgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200000, China
²Institute of Basic Medicine Science, Chinese PLA General Hospital, Beijing 100853, China
³Key Laboratory of Cancer Center, Chinese PLA General Hospital, Beijing 100853, China
⁴Department of Anesthesiology, Wuxi Third People’s Hospital, Wuxi, Jiangsu 214000, China
⁵Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing 100053, China
^*These authors contributed equally to this work
^#Co-senior authors

Published: March 30, 2018

This article has been corrected: Dr. Meiqing Lou is included as a co-corresponding author.

Correspondence to: Hao Wu, email: [email protected]

Correspondence to: Meiqing Lou, email: [email protected]

Original article: Oncotarget. 2018; 9:706-717 DOI: https://doi.org/10.18632/oncotarget.23091.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 25063

Publication Alerts

Post-Publication Promotion

Publication Discount

Corrections:

Correction: The dual PI3K/mTOR inhibitor dactolisib elicits anti-tumor activity in vitro and in vivo